Cagrilintide Benefits including Uses
Cagrilintide is an investigational weight-loss medication developed by Novo Nordisk.
Moreover, it is a long-acting amylin analogue used with diet and exercise, and sometimes with semaglutide, to aid weight management.
First, How It Works.
Additionally, Cagrilintide mimics amylin’s action as a naturally occurring hormone secreted by the pancreas alongside insulin.
Moreover, amylin contributes to controlling appetite and food intake. Cagrilintide’s main mechanisms include:
-
As a result, slowing gastric emptying prolongs the feeling of fullness after meals.
-
Reducing appetite – Signals to the brain help reduce hunger and cravings.
-
Decreasing calorie intake – Over time, this can help create a calorie deficit for weight loss.
Potential Benefits
Significant weight loss when used alone or with semaglutide
Improved metabolic health markers, such as blood sugar control and lipid profile
Once-weekly injection for convenience
Dual action when paired with GLP-1 agonists, potentially offering better results than either drug alone
Research & Clinical Data
Early and mid-stage clinical trials have shown promising results:
Participants using cagrilintide (with or without semaglutide) experienced substantial weight reductions compared to placebo.
Combination therapy appears to outperform semaglutide alone in percentage body weight lost.
Side Effects & Considerations
Commonly reported side effects are similar to those of other gut hormone-based therapies:
Nausea
Vomiting
Constipation
Diarrhea
These effects are usually mild to moderate and may improve as the body adapts.
Current Status
Cagrilintide is still in clinical development and has not yet received full regulatory approval in most countries.
Ongoing studies are assessing its safety, efficacy, and long-term benefits, especially in combination with semaglutide.





Reviews
There are no reviews yet.